This protocol covers the management of metastatic or unresectable urothelial carcinoma in patients who meet specific fitness and organ-function criteria — including an ECOG performance status of 0–2, a glomerular filtration rate of at least 30 mL/min, adequate overall organ function, and eligibility for enfortumab vedotin–based therapy.
Patients with eGFR ≥ 30 mL/min, ECOG PS 0–2, and adequate organ functions who are eligible for enfortumab vedotin represent the population for whom combination antibody-drug conjugate plus checkpoint inhibitor therapy is the established standard of care. These major eligibility criteria — performance status, renal function, and organ adequacy — together define who is deemed fit for this combination approach.
Within this protocol, treatment selection extends to targeted systemic options guided by tumour molecular biomarker status, with distinct therapeutic pathways available depending on specific tumour characteristics. The full algorithm — including sequencing, biomarker-driven pathway selection, and additional options such as clinical trial enrolment or supportive care — is detailed in the complete protocol.
Full regimen details, eligibility criteria per option, and decision sequencing available via the link below.